NPCE NeuroPace Inc

Price (delayed)

$16.37

Market cap

$558.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.65

Enterprise value

$612.95M

?
Relative Growth: Rel. Growth: 51
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 34

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating ...

Highlights
NeuroPace's gross profit has increased by 24% YoY
NeuroPace's EPS has increased by 22% YoY
NPCE's equity is down by 40% year-on-year and by 24% since the previous quarter
NeuroPace's quick ratio has decreased by 22% YoY

Key stats

What are the main financial stats of NPCE

NPCE stock price

How has the NeuroPace stock price performed over time
Intraday
3.09%
1 week
-5.87%
1 month
-3.14%
1 year
24.3%
YTD
6.02%
QTD
24.49%

Financial performance

How have NeuroPace's revenue and profit performed over time
Revenue
$99.53M
Gross profit
$77.93M
Operating income
-$16.76M
Net income
-$21.57M
Gross margin
78.3%
Net margin
-21.7%
NeuroPace's operating margin has increased by 27% YoY but it has decreased by 3.1% from the previous quarter
The net margin has increased by 26% YoY
NeuroPace's gross profit has increased by 24% YoY
NPCE's revenue is up by 18% year-on-year

Price vs fundamentals

How does NPCE's price correlate with its fundamentals

Growth

What is NeuroPace's growth rate over time

Valuation

What is NeuroPace stock price valuation
P/E
N/A
P/B
38.13
P/S
5.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.16
NeuroPace's EPS has increased by 22% YoY
The price to book (P/B) is 160% higher than the 5-year quarterly average of 14.2 and 56% higher than the last 4 quarters average of 23.7
NPCE's equity is down by 40% year-on-year and by 24% since the previous quarter
NPCE's price to sales (P/S) is 35% more than its 5-year quarterly average of 4.0 and 25% more than its last 4 quarters average of 4.3
NPCE's revenue is up by 18% year-on-year

Efficiency

How efficient is NeuroPace business performance
NeuroPace's ROE has increased by 37% YoY but it has decreased by 14% from the previous quarter
NeuroPace's return on sales has increased by 23% YoY but it has decreased by 6% QoQ
The company's return on assets rose by 18% YoY but it fell by 3% QoQ
NPCE's ROIC is up by 7% year-on-year but it is down by 6% since the previous quarter

Dividends

What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NPCE.

Financial health

How did NeuroPace financials performed over time
NPCE's total assets is 17% higher than its total liabilities
NeuroPace's quick ratio has decreased by 22% YoY
The company's current ratio fell by 19% YoY
NeuroPace's debt to equity has surged by 62% YoY and by 31% QoQ
NPCE's equity is down by 40% year-on-year and by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.